Patents by Inventor Nancy Sever

Nancy Sever has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pharmaceutical formulations for subcutaneous administration
    Patent number: 12251365
    Abstract: The present disclosure relates to compositions of levodopa 4?-monophosphate and carbidopa 4?-monophosphate having a weight by weight ratio of about 20:1 and methods of treating Parkinson's disease and associated conditions by subcutaneous administration of such compositions.
    Type: Grant
    Filed: November 15, 2019
    Date of Patent: March 18, 2025
    Assignees: AbbVie Inc., AbbVie Deutschland Gmbh & Co. KG
    Inventors: Ehab Moussa, Matthew Rosebraugh, Feroz Jameel, Nancy Sever, Maurizio F. Facheris, Weining Z Robieson, Charles S. Locke, Sven Stodtmann
  • Pharmaceutical Formulations for Subcutaneous Administration
    Publication number: 20200155578
    Abstract: The present disclosure relates to compositions of levodopa 4?-monophosphate and carbidopa 4?-monophosphate having a weight by weight ratio of about 20:1 and methods of treating Parkinson's disease and associated conditions by subcutaneous administration of such compositions.
    Type: Application
    Filed: November 15, 2019
    Publication date: May 21, 2020
    Applicant: AbbVie Inc.
    Inventors: Ehab Moussa, Matthew Rosebraugh, Feroz Jameel, Nancy Sever, Maurizio F. Facheris, Weining Z. Robieson, Charles S. Locke, Sven Stodtmann
  • Solid Pharmaceutical Compositions for Treating HCV
    Publication number: 20160375017
    Abstract: The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first layer which comprises 100 mg Compound 1, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion; and (2) a second layer which comprises 40 mg Compound 2, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion.
    Type: Application
    Filed: July 18, 2016
    Publication date: December 29, 2016
    Applicant: AbbVie Inc.
    Inventors: Katharina Asmus, Yi Gao, Colleen Garrett, Harald Hach, Adivaraha Jayasankar, Kyeremateng Samuel, Ute Lander, Thomas Mueller, Marius Naris, Constanze Obermiller, Regina Reul, Katrin Schneider, Nancy Sever, Michael Simon, Benedikt Steitz, Ping Tong, Ulrich Westedt, Donghua Zhu
  • Stable amorphous cefdinir
    Publication number: 20060069079
    Abstract: The present invention relates to stable amorphous 7-[2-(2-aminothiazol-4-yl)-2-hydroxyiminoacetamide]-3-vinyl-3-cephem-4-carboxylic acid (syn isomer), methods for its preparation, and pharmaceutical compositions comprising stable amorphous 7-[2-(2-aminothiazol-4-yl)-2-hydroxyiminoacetamide]-3-vinyl-3-cephem-4-carboxylic acid (syn isomer).
    Type: Application
    Filed: September 27, 2004
    Publication date: March 30, 2006
    Inventors: Nancy Sever, Devalina Law
  • Stable amorphous Cefdinir
    Publication number: 20060029674
    Abstract: The present invention relates to stable amorphous 7-[2-(2-aminothiazol-4-yl)-2-hydroxyiminoacetamide]-3-vinyl-3-cephem-4-carboxylic acid (syn isomer), methods for its preparation, and pharmaceutical compositions comprising stable amorphous 7-[2-(2-aminothiazol-4-yl)-2-hydroxyiminoacetamide]-3-vinyl-3-cephem-4-carboxylic acid (syn isomer).
    Type: Application
    Filed: April 11, 2005
    Publication date: February 9, 2006
    Inventors: Nancy Sever, Devalina Law